Gilead Sciences Inc. has described thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among other disorders.

Forge Therapeutics Inc. has synthesized new UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Gram-negative bacterial infections.

Otcpharm JSC has described 2-acetamido-6-hydroxy-benzothiophene compounds reported to be useful for the treatment of influenza A infections.

Idorsia Ltd. has discovered hydroxyheterocycloalkane-carbamoyl derivatives acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors.

Astellas Pharma Inc. has described new quinazoline GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. It inhibited 3D anchorage-independent proliferation of KRAS(G12D) mutant-positive AsPC-1 cancer cells (IC50 = 23 nM) in Celltiter-Glo assays.

Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.

Jiangsu Hengrui Medicine Co. Ltd. has described prodrugs of tolvaptan acting as vasopressin V2 receptor antagonists.

Medshine Discovery Inc. has discovered 5,6,7,8-tetrahydropyridine[3,4-d] pyrimidine compounds acting as GTPase KRAS inhibitors.